| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Other receivables | NaN | NaN | 369,157 | 188,116 |
| Cash and cash equivalents | 18,519,784 | 24,711,356 | 23,075,261 | 5,035,006 |
| Prepaid expenses | 1,770,844 | NaN | NaN | NaN |
| Other receivables | 687,756 | NaN | 53,159 | NaN |
| Other current assets | 680,753 | 2,352,523 | 1,506,603 | 1,379,295 |
| Total current assets | 21,659,137 | 27,063,879 | 25,004,180 | 6,602,417 |
| Property and equipment, net | 1,448,990 | 1,558,890 | 1,657,255 | 1,651,656 |
| Operating lease right-of-use assets | 969,256 | 1,097,580 | 824,693 | 955,651 |
| Finance lease right-of-use asset | 1,308,581 | 1,744,775 | 2,244,073 | 2,699,899 |
| Other non-current assets | 2,442,450 | 1,009,439 | 1,018,373 | 1,069,902 |
| Total assets | 27,828,414 | 32,474,563 | 30,748,574 | 12,979,525 |
| Accounts payable | 1,231,086 | 1,200,686 | 1,844,862 | 1,762,600 |
| Accrued expenses | 529,325 | 725,184 | 2,324,931 | 2,523,603 |
| Deferred grant funding | 18,150,459 | 19,651,452 | 14,557,265 | 12,326,879 |
| Current portion of liability related to the sale of future royalties | 12,035 | 11,711 | 10,542 | 187,966 |
| Current portion of lease liabilities, operating | 598,556 | 602,552 | 609,224 | 588,478 |
| Current portion of lease liability, finance | 597,552 | 1,494,102 | 1,869,570 | 1,831,617 |
| Lease liability long-term, finance | NaN | NaN | 165,186 | 164,412 |
| Total current liabilities | 21,119,013 | 23,685,687 | 21,216,394 | 19,221,143 |
| Deferred revenue, non-current | NaN | 0 | 1,000,000 | 1,000,000 |
| Liability related to the sale of future royalties, net | 5,556,697 | 5,386,877 | 5,220,525 | 4,879,024 |
| Lease liabilities long-term, operating | 418,253 | 559,365 | 288,566 | 448,206 |
| Total liabilities | 27,093,963 | 29,631,929 | 27,890,671 | 25,712,785 |
| Preferred stock, 0.01 par value, 5,000,000 shares authorized 4,999,620 and 0 designated series a convertible preferred stock at march31, 2026 and december31, 2025, respectively 65,640 and 0 issued and outstanding at march31, 2026 and december31, 2025, respectively. liquidation preference of 328,200 and 0 at march31, 2026 and december31, 2025, respectively | 656 | NaN | NaN | NaN |
| Common stock, 0.0001 par value 240,000,000 shares authorized 14,559,502 and 14,499,502 shares issued and outstanding at march31, 2026 and december31, 2025, respectively | 1,456 | 1,450 | 1,393 | 903 |
| Additional paid-in capital | 192,798,213 | 191,951,711 | 190,499,662 | 171,353,083 |
| Accumulated other comprehensive loss | -377,081 | -421,623 | -395,966 | -402,826 |
| Accumulated deficit | -191,688,793 | -188,688,904 | -187,247,186 | -183,684,420 |
| Total stockholders' equity | 734,451 | 2,842,634 | 2,857,903 | -12,733,260 |
| Total liabilities and stockholders' equity | 27,828,414 | 32,474,563 | 30,748,574 | 12,979,525 |
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)